Sugi Predict

Sugi Predict / Compounds / SCHEMBL105892

SCHEMBL105892

SCHEMBL105892

C[Si](C)(C)c1ccc(C(=O)O)cc1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.74
▸ TSHR P16473 3/20 0.60
▸ TP53 P04637 1/20 0.60
▸ ALDH1A1 P00352 2/20 0.54
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ SRD5A2 P31213 4/20 0.52
▸ CA1 P00915 3/20 0.50
▸ CA2 P00918 3/20 0.50
▸ CA12 O43570 1/20 0.50
▸ CA3 P07451 1/20 0.50
▸ TYR P14679 1/20 0.50
▸ DRD1 P21728 1/20 0.50
▸ CA4 P22748 1/20 0.50
▸ CA6 P23280 1/20 0.50
▸ CA5A P35218 1/20 0.50
▸ CA7 P43166 1/20 0.50
▸ CA9 Q16790 1/20 0.50
▸ CA14 Q9ULX7 1/20 0.50
▸ CA5B Q9Y2D0 1/20 0.50
▸ NAPRT Q6XQN6 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3482898 0.85 HPGD (1.00) HPGDTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL1930618 0.83 HPGD (0.71) HPGDTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL30080293 0.82 ALDH1A1 (0.52) HPGDALDH1A1SRD5A2
SCHEMBL20010800 0.82 CES2 (0.52) HPGDCES2CES1
SCHEMBL30910037 0.81 HPGD (0.68) HPGDTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL25218061 0.80 XDH (0.63) HPGDTP53ALDH1A1SMN1; SMN2ALOX15
SCHEMBL11910715 0.80 HPGD (0.50) HPGDALDH1A1SMN1; SMN2
SCHEMBL8018862 0.80 HPGD (0.48) HPGDTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL30485900 0.79 HPGD (0.65) HPGDTSHRTP53ALDH1A1SMN1; SMN2
SCHEMBL2786186 0.79 HPGD (0.65) HPGDTSHRTP53ALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4000265-A SILICON COMPOUNDS SOCIETE CORTIAL (FR) 1976-12-28 — — US claimed
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI-AVENTIS RECHERCHE & DÉVELOPPEMENT (FR) 2026-01-22 — — US disclosed
EP-4558500-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF Sanofi (FR) 2025-05-28 — — EP disclosed
WO-2024017977-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF SANOFI (FR) 2024-01-25 — — WO disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-9487517-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-11-08 — — US disclosed
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-01-21 — — US disclosed
EP-2433940-B9 SPIROIMIDAZOLONE DERIVATIVE CHUGAI PHARMACEUTICAL CO LTD (JP) 2015-10-28 — — EP disclosed
US-9169254-B2 Spiroimidazolone derivative CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-10-27 — — US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US disclosed
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase ROCHE PALO ALTO LLC 2009-07-23 — — US disclosed
WO-2009077334-A1 NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2009-06-25 — — WO disclosed
WO-2009053269-A1 NOVEL KINASE INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2009-04-30 — — WO disclosed
US-20090105209-A1 BTK protein kinase inhibitors ROCHE PALO ALTO LLC 2009-04-23 — — US disclosed
WO-2009020589-A1 SILICON DERIVATIVES AS HISTONE DEACETYLASE INHIBITORS MERCK & CO., INC. (US) 2009-02-12 — — WO disclosed
US-6020426-A BLOCK OR GRAFT COPOLYMER FUJI XEROX CO., LTD. (JP) 2000-02-01 — — US disclosed
US-4868241-A POLYVINYL ALCOHOL MODIFIED WITH BENZOIC ACID DERIVATIVE AMERICAN CYANAMID COMPANY (US) 1989-09-19 — — US disclosed
EP-0231922-A2 Electron beam and X-ray resists AMERICAN CYANAMID COMPANY (US) 1987-08-12 — — EP disclosed
US-4000265-A SILICON COMPOUNDS SOCIETE CORTIAL (FR) 1976-12-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186898-A1 Inhibitors of bruton's tyrosine kinase BTK, SYK, LYN HPGD 3682/4885TSHR 1088/4885TP53 2098/4885
US-20090105209-A1 BTK protein kinase inhibitors BTK, SYK, LYN HPGD 3768/4885TSHR 1229/4885TP53 1892/4885
US-20160016956-A1 SPIROIMIDAZOLONE DERIVATIVE WNK3, REN, SGK3 HPGD 2068/4885TSHR 914/4885TP53 3159/4885
US-20260022116-A1 IMIDAZOPYRIDINE COMPOUNDS, PREPARATION THEREOF AND THERAPEUTIC USES THEREOF MAPK1, MAPK3, MAPK6 HPGD 2464/4885TSHR 1369/4885TP53 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.